Impact of COVID-19 pandemic on the etiology and characteristics of

- community-acquired pneumonia among children requiring
- 3 bronchoalveolar lavage in northern China
- 4 Rui-han Liu^{1,2¶}, Yu-yan Zhang^{1¶}, Zhou-hua Lu¹, Chang-qing Shen¹, Jin Wang¹,
- 5 Qing Zhao¹, Tong-shu Hou³, Feng-hai Niu¹, Qing-xia Kong^{1*}, Jun Ning^{1*}, Lei
- 6 Yang^{1,2*}

1

- ⁷ Affiliated Hospital of Jining Medical University, Jining Medical University,
- 8 Jining, Shandong, China
- ⁹ ²College of TCM, Shandong University of Traditional Chinese Medicine, Jinan,
- 10 Shandong, China
- ³The Second Clinical Medical College, Binzhou Medical University, Yantai,
- 12 Shandong, China
- 13 These authors contributed equally to this work.
- * co-corresponding authors
- 15 Corresponding authors
- 16 E-mail: kxdqy8@sohu.com(QXK)
- 17 E-mail: 18678766989@163.com(JN)
- 18 E-mail: yanglei8224982@163.com(LY)

Abstract

19

20

22

23

24

25

27

28

29

30

31

32

33

34

35

36

37

38

39

40

Background:

To investigate the etiology and clinical characteristics of community-acquired

pneumonia (CAP) among children requiring bronchoalveolar lavage (BAL) and

analyze the impact of the coronavirus disease 2019 (COVID-19) pandemic on

the pathogen spectrum and clinical manifestations.

Methods:

26 Children <14 years old hospitalized with CAP requiring BLA were enrolled

between February 2019 to January 2020 and August 2021 to July 2022.

Multiplex reverse transcription polymerase chain reaction (mRT-PCR) was

used for pathogen detection. The demographic and clinical characteristics

were compared between different pathogen-type infection groups, and before

and during the COVID-19 pandemic.

Results:

Pathogen was detected in 91.66% (1363/1487) children. Mycoplasma

pneumoniae, adenovirus and human rhinovirus were the most frequently

detected pathogens. The frequency of detection of virus infections and

co-infections was decreased during the pandemic, but the detection of atypical

bacterial infections was increased. The clinical manifestations and the results

of CT scans and fiberoptic bronchoscopy showed a significant difference

between different types of pathogen infection, and lung inflammation was

reduced during the COVID-19 pandemic compared with before the pandemic.

Conclusions:

inflammation

in

children

41

47

M. pneumoniae infection might be the greatest pediatric disease burden leading to CAP in northern China. Wearing masks and social distancing in public places during the COVID-19 pandemic effectively reduced the transmission of respiratory viruses, but it did not reduce the infection rate of M. pneumoniae. In addition, these interventions significantly reduced lung

compared

with

before

the

pandemic.

Introduction

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

Community-acquired pneumonia (CAP) is a common infection that presents a serious public health threat among children under 5 years of age. CAP was responsible for 13.9% of childhood deaths among the under-5s worldwide in 2019[1]. Although this was more than 1,001,000 fewer deaths compared with the year 2000, the number of complicated and severe pneumonia cases has increased considerably over the past two decades[2,3]. Following the introduction of the pneumococcal conjugate vaccine and the Haemophilus influenzae type b vaccine, respiratory viruses and atypical bacteria have become the most frequent etiologic agents in recent years[4]. The outbreak of coronavirus disease 2019 (COVID-19) constitutes a substantial health burden across the globe. To control the COVID-19 pandemic, governments around the world implemented a series of non-pharmaceutical interventions (NPIs), such as mandated facial masks, encouraged social distancing, remote working, online teaching, stay-at-home orders and travel restrictions. Studies have shown that the preventive measures useful in containing COVID-19 also seemed to be effective in preventing the transmission of other respiratory viruses[5-11]. Considering the impact of etiology on disease severity, mortality and long-term sequelae in children with CAP[12], it is necessary to identify the causative pathogen. Nasopharyngeal swabs or aspirate specimens are usually used for pathogen detection in children with CAP. However, the detection of microorganisms from the upper respiratory tract may not directly correlate with the pathogenic agents of pneumonia[13]. Over the past two decades, fiberoptic bronchoscopy (FB) and bronchoalveolar lavage (BAL) have become important diagnostic and therapeutic procedures for severe pneumonia. Bronchoalveolar lavage fluid (BALF) collected directly from the foci of inflammation can be used as reliable samples for pathogen identification[14]. Furthermore, advances in molecular detection technology have contributed to rapid and accurate pathogen identification. Automated capillary electrophoresis combined with multiplex reverse transcription polymerase chain reaction (mRT-PCR) has been developed to detect microorganisms, at reasonable cost and acceptable levels of sensitivity and specificity[15]. In this study, we report and discuss the impact of the COVID-19 pandemic on the spectrum of common respiratory pathogens among children with CAP requiring FB plus BAL in northern China. Additionally, changes in the pathogen spectrum and the clinical manifestations in the children were analyzed systematically and compared prior to the COVID-19 pandemic (February 2019) to January 2020) and during the COVID-19 pandemic (August 2021 to July 2022).

Materials and methods

89 Ethics approval

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

This study was approved by the Ethics Committee of the Affiliated Hospital of

Jining Medical University (No.: 2020C076).

Study population

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

Between February 2019 to January 2020 and August 2021 to July 2022, a total of 1487 children under the age of 14 who required BAL were included in our study. It was ensured by experienced physicians that the following inclusion criteria were met. (1) All of the children were in the acute stage of pneumonia. (2) Symptoms persisted for at least 7 days after the initiation of treatment and/or the patient was not responding to treatment, or breathing was labored. or the child became distressed or agitated, or their oxygen saturation level was < 92%. (3) Auscultation revealed decreased/absent breath sounds, or tubular breath sounds, and or a repeated fixed wheeze. (4) Radiographic inspection revealed pulmonary atelectasis, or pulmonary emphysema, or mediastinal emphysema, or pulmonary consolidation. Exclusion criteria were as follows: children with immunodeficiency disease, congenital heart disease, tracheostomy tube, cystic fibrosis, hemopoietic system malignant tumor, recent hematopoietic stem-cell or solid-organ transplant, children with an alternative respiratory disorder diagnosis or newborns less than 1 month old. Written informed consent was obtained from parents/guardians before children underwent FB plus BAL.

Sample and data collection

For the purpose of treatment, FB combined with BAL was performed by experienced bronchoscopists according to the recommendation of the European Respiratory Society Task Force[16]. Approximately 3 mL of BALF

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

was collected from each patient and the samples were aliquoted and stored at -80°C within 2 hours simultaneously. Diagnosis of the morphology under bronchoscopy was made by two experienced physicians[17,18]. The presence of pulmonary consolidation, infiltration, pleural effusion and pericardial effusion in the CT scans was considered evidence of pneumonia[19]. The CT scans were reviewed by three senior radiologists independently to ensure the accuracy and consistency of the diagnosis. The other clinical data were extracted from electronic medical records after the patient was discharged. Pathogen detection The SureX 13 respiratory pathogen multiplex kit (Ningbo Health Gene Technologies Ltd.) was used to simultaneously detect common virus and atypical bacteria in 200 µL of BALF. The mRT-PCR products were analyzed on the Applied Biosystems 3500Dx Genetic Analyzer with LIZ500 as the internal standard, and then analyzed with GeneMapper 4.1 software (Thermo Fisher Scientific, Waltham, MA, USA). A viral or atypical bacterial pathogen was considered to be present if influenza A virus (Flu A, including 2009 H1N1 pandemic and H3N2), influenza B virus (Flu B), parainfluenza virus (PIV), adenovirus (AdV), respiratory syncytial virus (RSV), human rhinovirus (HRV), human metapneumovirus bocavirus (HBoV), coronavirus (CoV), Mycoplasma (hMPV), human

pneumoniae or Chlamydophila pneumoniae was detected in the BALF.

Co-infection was considered when two or more viral or atypical bacterial pathogens were detected in one child.

Statistical analysis

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

Considering the similar clinical features observed between children with virus-virus co-infections and single virus infections, these cases were combined into the virus group in the tables. This also applied to those with one or two atypical bacterial infections, who were combined in the atypical bacterium group. The clinical characteristics of enrolled children were stratified and described according to the following groups: virus or atypical bacterium only infection, and co-infection (virus-atypical bacterium infections). All statistical analyses were performed using SAS software, version 9.4 (SAS Institute Inc., NC, USA). The median and quartile [M (P25, P75)] values were used to describe quantitative data with a non-normal distribution, and the frequency (component ratio) [n (%)] was used to describe classified data. The Chi-squared test was used to analyze differences in sex, age, the season of disease onset and the infecting pathogens between samples collected before and during the COVID-19 pandemic. The Kruskal-Wallis H test was used to compare the time from illness onset to admission, the duration of hospitalization, and the presence of a fever and cough in different groups between different time periods. Fisher's exact test was used to compare the difference in the proportion of different pathogens between samples taken before and during the COVID-19 pandemic. Trends in the infection rates of various pathogens in different age groups were assessed by the Cochran–Armitage trend test. The differences in clinical manifestations, CT scans and FB results between the various groups and different time periods were also analyzed by Fisher's exact test. A probability (p) value less than 0.05 was considered statistically significant. For pairwise comparison of multiple groups of samples, Bonferroni correction was used to inspect the standard of each comparison, $\alpha' = 0.01667 (0.05/3)$.

Results

Demographic characteristics

From February 2019 to January 2020 and August 2021 to July 2022, 696 and 791 children were enrolled in this study, respectively (Table 1). A total of 54.74% of the children were boys, and the median age was 70.51±32.79 months. The median time from illness onset to admission and the median duration of hospitalization were 8 (6,10) days and 7 (6,9) days, respectively. The proportion of children undergoing FB combined with BAL gradually increased with age (X²/Z=54.0288, P<0.001), and the proportion of children affected during autumn was significantly higher than that in the other seasons.

Compared with before the COVID-19 pandemic, the median time from illness onset to hospitalization was reduced [8 (6,11) days vs 7 (6,10) days; P=0.0031] and the median hospitalization time was also reduced [8 (7,9) days vs 7 (6,8) days; P<0.001] in the children enrolled during the COVID-19 pandemic. During the COVID-19 pandemic, the pathogen detection rate

Table 1 Demographic characteristics of children with community-acquired pneumonia requiring Flexible bronchoscopy and bronchoalveolar lavage

Variables	Total	Before	Ongoing	X^2/Z	Р	
Number	1487	791		-	-	
Sex (male), No. (%) ^a	814(54.74)	385(55.32)	429(54.24)	0.1746	0.676	
Time from illness onset to admission (days), mean(P25, P75) ^b	8(6,10)	8(6,11)	7(6,10)	8.748	0.0031	
Duration of hospitalization (days), mean(P25, P75) b	7(6,9)	8(7,9)	7(6,8)	48.1227	<0.001	
Age (mo), mean ± SD ^a	70.51±32.79	64.41±32.43	75.87±32.19			
age < 3 yrs, No. (%)	229(15.40)	149(21.41)	80(10.11)			
3 yrs. ≤ age < 5 yrs, No. (%)	357(24.01)	170(24.43)	187(23.64)			
5 yrs. ≤ age < 7 yrs, No. (%)	427(28.72)	207(29.74)	220(27.81)	54.0288	<0.001	
7 yrs. ≤ age < 14 yrs, No. (%)	474(31.88)	170(24.43)	304(38.43)			
Incident season, No. (%) a		•				
Spring (Mar, Apr, May)	170 (11.43)	116(16.67)	54(6.83)			
Summer (Jun, Jul, Aug)	237 (15.94)	89(12.79)	148(18.71)	40.00=5		
Fall (Sep, Oct, Nov)	640(43.04)	291(41.81)	349(44.12)	40.2873	<0.001	
Winter (Dec, Jan, Feb)	440(29.59)	200(28.74)	240(30.34)			

Data are no. (%) of children, unless otherwise indicated. Percentages were calculated using the number of children with available data, rather than the total number.

a. Chi-square test was used to analyze the differences in gender, age and onset seasons between before COVID-19 pandemic and during COVID-19

- pandemic.
- b. Kruskal-Wallis H Test was used to compare the time from illness onset to admission and duration of hospitalization in different groups between different
- period.

decreased from 20% to ~10% in children under 3 years of age and increased from 25% up to ~40% in children aged over 7 years. There was also a statistical difference in the season of illness onset among the children (X²/Z=40.2873, P<0.001), with a lower incidence of disease in spring (16.67% vs 6.83%) and a higher incidence in summer (12.79% vs 18.71%) during the COVID-19 pandemic (Table 1).

Pathogen spectrum

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

Among the enrolled children, ≥1 pathogen was detected in 91.66% (1363/1487) of children and the pathogen detection rate gradually increasing with age (Z=-6.425, P<0.001). The specific pathogens detected are listed in Table 2, sorted by descending detection rates. AdV (n=64, 4.30%), HRV (n=41, 2.76%), PIV (n=21, 1.41%) and Flu B (n=21, 1.41%) were the most common viral pathogens among the enrolled cases. There were statistically significant differences in the age of children infected with viruses, with the number of children infected with viruses decreasing with increased age, except for Flu B (P=0.1927) and hMPV (P=0.1447). Children younger than 3 years were more vulnerable to AdV, PIV and RSV infection, whereas children older than 3 years were more susceptible to atypical bacterial infection. A total of 1254 (84.33%) cases were found to be infected with M. pneumoniae, and the number of children with M. pneumoniae infection increased with age (Z=-10.2742, P<0.001).

Compared with before the COVID-19 pandemic, the number of children

Table 2 Prevalence of causative respiratory pathogen according to age groups in children performed with FOB combined with BAL

Pathogen Detected	Total No. (%)	< 3 years No. (%)	3–5 years No. (%)	5–7 years No. (%)	7–14 years No. (%)	Z	р
Participants, n	1487	229	357	427	474	-	-
≥1 pathogen detected	1363(91.66)	186(81.22)	319(89.36)	407(95.32)	451(95.15)	-6.425	<0.001
Virus							
AdV ^a	64(4.30)	19(8.30)	25(7.00)	13(3.04)	7(1.48)	4.9844	<0.001
HRV a	41(2.76)	10(4.37)	11(3.08)	11(2.58)	9(1.90)	1.8833	0.0298
PIV ^a	21(1.41)	12(5.24)	5(1.40)	2(0.47)	2(0.42)	4.6023	<0.001
Flu B	21(1.41)	5(2.18)	2(0.56)	11(2.58)	3(0.63)	0.8681	0.1927
RSV ^a	19(1.28)	11(4.80)	2(0.56)	4(0.94)	2(0.42)	3.8454	<0.001
Flu A ^a	10(0.67)	6(2.62)	2(0.56)	0(0.00)	2(0.42)	2.9073	0.0018
HBoV ^a	8(0.54)	5(2.18)	1(0.28)	1(0.23)	1(0.21)	2.7325	0.0031
hMPV	8(0.54)	2(0.87)	2(0.56)	3(0.7)	1(0.21)	1.0593	0.1447
CoV ^a	2(0.13)	1(0.44)	1(0.28)	0(0.00)	0(0.00)	1.6974	0.0448
Atypical bacteria							
M.pneumonia ^a	1254(84.33)	142(62.01)	291(81.51)	381(89.23)	440(92.83)	-10.2742	<0.001
C.pneumoniae	4(0.27)	1(0.44)	0(0.00)	1(0.23)	2(0.42)	-0.4335	0.3323

Data are no. (%) of children, unless otherwise indicated. Percentages were calculated using the number of children with available data, rather than the total number.

 $^{^{}a}p$ <0.05, Cochran-Armitage Trend Test was used to compare trends of infection rates of various pathogens in different age groups.

Table 3 Distribution of various pathogens in children patients performed with FOB combined with BAL

Pathogen Detected	Total, No. (%)	Before, No. (%)	Ongoing, No. (%)		
Participants, n	1487	696	791	X ² /Z	р
Virus	107(7.20)	69(9.91)	38(4.80)		
Atypical bacteria	1177(79.15)	515(73.99)	662(83.69)	00.4440	10.004
Co-infection	79(5.31)	51(7.33)	28(3.54)	28.1146	<0.001
No pathogenic detected	124(8.34)	61(8.76)	63(7.96)		
Virus)
AdV ^a	64(4.30)	40(5.75)	24(3.03)	0.0105	
HRV ^a	41(2.76)	29(4.17)	12(1.52)	0.0022	
PIV	21(1.41)	13(1.87)	8(1.01)	0.1894	
Flu B ^a	21(1.41)	15(2.16)	6(0.76)	0.0271	
RSV	19(1.28)	8(1.15)	11(1.39)	0.8182	
Flu A ^a	10(0.67)	10(1.44)	0(0.00)	0.0005	
HBoV ^a	8(0.54)	7(1.01)	1(0.13)	0.0293	
hMPV	8(0.54)	3(0.43)	5(0.63)	0.7303	
CoV	2(0.13)	2(0.29)	0(0.00)	0.2189	
Atypical bacteria				ı)
M.pneumonia ^a	1254(84.33)	564(81.03)	690(87.23)	0.0013	
C.pneumoniae ^a	4(0.27)	4(0.57)	0(0.00)	0.0478	

Data are no. (%) of children, unless otherwise indicated. Percentages were calculated using the number of children with available data, rather than the number.

 $^{^{}a}p$ <0.05, Fisher's Exact Test was used to compare the differences between alone and co-infection of each pathogen in different period.

infected with AdV (5.75% vs 3.03%, P=0.0105), HRV (4.17% vs 1.52%, P=0.0022), Flu B (2.16% vs 0.76%, P=0.0271), Flu A (1.44% vs 0.00%, P=0.0005) and HBoV (1.01% vs 0.13%, P=0.0293) decreased significantly. Therefore, the total proportion of cases of viral infection (9.91% vs 4.80%) and co-infection (7.33% vs 3.54%) decreased significantly. Whereas the proportion of cases of *M. pneumoniae* infection had a further increasing that compared with before the pandemic (87.23% vs 81.03%, P=0.0013) (Table 3).

Clinical characteristics between three infection groups

Children with viral infection showed the shortest duration of fever [4 (0,6) days], while those with atypical bacterial infection [7 (5,9) days vs 4 (0,6) days, P<0.001] or co-infection [7 (4,10) days vs 4 (0,6) days, P=0.0002] showed longer duration of fever, and the differences among the three groups were statistically significant (P<0.001). The incidence of wheezing in children infected with virus (18.69% vs 3.91%, P<0.001) and those with co-infection (15.19% vs 3.91%, P=0.0001) was significantly higher than in those with atypical bacterial infection (3.91%). Compared with the atypical bacterial infection group, viral infection made children more prone to dyspnea (8.41% vs 1.44%, P=0.0001), diarrhea (15.89% vs 6.73%, P=0.0019), rhonchi (47.66% vs 28.63%, P=0.0003) and chest indrawing (9.35% vs 1.7%, P=0.0001). Decreased breath sounds (59.64%) and rales (66.10%) were the most common signs in the atypical bacterial infection group. No remarkable differences in the duration of cough, fatigue, lack of appetite, abdominal pain,

Table 4 Comparison of clinical and laboratory findings according to respiratory pathogens in children performed with FOB combined with BAL

Characteristic	Total N=1363	Virus ¹ N=107	Atypical Bacteria ² N=1177	Co-infection ³ N=79	P value	P value c (1-2)	P value ° (1-3)	P value ^c (2-3)
Clinical data								
Duration of fever,mean(P25, P75) a	7(5,8)	4(0,6)	7(5,9)	7(4,10)	<0.001	<0.001	0.0002	0.7161
Duration of cough,mean(P25, P75) ^a	7(5,9)	6(4,13)	7(5,9)	8(5,11)	0.3451	0.5847	0.8112	0.1543
Fatigue ^b	17(1.25)	3(2.80)	12(1.02)	2(2.53)	0.1035	0.1228	1	0.2184
Dyspnea ^b	29(2.13)	9(8.41)	17(1.44)	3(3.80)	0.0001	0.0001	0.2422	0.1262
Wheezing ^b	78(5.72)	20(18.69)	46(3.91)	12(15.19)	<0.001	<0.001	0.5621	0.0001
Lack of appetite ^b	830(60.9)	66(61.68)	719(61.09)	45(56.96)	0.7557	1	0.5476	0.4769
Abdominal pain ^b	227(16.65)	15(14.02)	201(17.08)	11(13.92)	0.6354	0.5000	1	0.5375
Diarrhea ^b	100(7.34)	17(15.89)	75(6.37)	8(10.13)	0.0019	0.0012	0.2845	0.2356
Chest pain ^b	40(2.93)	4(3.74)	33(2.80)	3(3.80)	0.5852	0.5424	1	0.4907
Physical sign								
Decreased breath sounds ^b	770(56.49)	35(32.71)	702(59.64)	33(41.77)	<0.001	<0.001	0.2208	0.0021
Rales ^b	887(65.08)	60(56.07)	778(66.10)	49(62.03)	0.0957	0.0436	0.4535	0.4640
Rhonchi ^b	415(30.45)	51(47.66)	337(28.63)	27(34.18)	0.0003	<0.001	0.0727	0.3062

Tachypnea ^b	47(3.45)	5(4.67)	39(3.31)	3(3.80)	0.571	0.4065	1	0.744
Chest indrawing b	33(2.42)	10(9.35)	20(1.70)	3(3.80)	0.0001	<0.001	0.2437	0.1718
T scan								
Consolidation ^b	1034(75.86)	60(56.07)	926(78.67)	48(60.76)	<0.001	<0.001	0.5505	0.0007
Single lobar infiltrate ^b	519(38.08)	30(28.04)	465(39.51)	24(30.38)	0.0222	0.0222	0.7462	0.1215
Multilobar infiltrates (unilateral) b	377(27.66)	19(17.76)	333(28.29)	25(31.65)	0.0408	0.0177	0.0359	0.5214
Multilobar infiltrates (bilateral) b	436(31.99)	50(46.73)	358(30.42)	28(35.44)	0.0024	0.0007	0.135	0.3781
Pleural effusion ^b	236(17.31)	13(12.15)	211(17.93)	12(15.19)	0.2979	0.1445	0.6644	0.6486
Pericardial effusion ^b	37(2.71)	4(3.74)	29(2.46)	4(5.06)	0.2135	0.3478	0.7244	0.1485
beroptic bronchoscopy								
Mucosal hyperemia and/or edema b	820(60.16)	69(64.49)	714(60.66)	37(46.84)	0.0348	0.4699	0.0174	0.0176
Mucosal erosion and/or necrosis b	543(39.84)	38(35.51)	463(39.34)	42(53.16)	0.0348	0.4699	0.0174	0.0176
Bronchial mucus plugs b	224(16.43)	2(1.87)	214(18.18)	8(10.13)	<0.001	<0.001	0.0193	0.0919
Plastic bronchitis ^b	171(12.55)	2(1.87)	162(13.76)	7(8.86)	0.0002	<0.001	0.0382	0.3048
Bronchial atresia ^b	23(1.69)	6(5.61)	14(1.19)	3(3.80)	0.0023	0.0043	0.7352	0.0861
Bronchiectasis ^b	11(0.81)	5(4.67)	5(0.42)	1(1.27)	0.0006	0.0007	0.2433	0.3233

Group 1, Virus alone infection; group 2, Atypical Bacteria alone infection; group 3, Virus-Atypical bacteria co-infection.

- a. Kruskal-Wallis H tests were conducted to compare groups.
- b. Fisher exact tests were conducted to compare groups.
- 242 C. Bonferroni correction was conducted to pairwise comparison of multiple groups of samples.

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

chest pain and tachypnea were observed between the three groups (Table 4). In CT scan findings, both consolidation and infiltration revealed prominent differences among the different infection groups. Atypical bacterial infection was most likely to cause consolidation (P<0.001) and single lobar infiltration (P=0.0222). Compared with the atypical bacterial infection group, the virus infection group was more likely to lead to bilateral multilobar infiltration (46.73% vs 30.42%, P=0.0007), whereas unilateral multilobar infiltration was more common in the atypical bacterial infection group than in the virus infection group (28.29% vs 17.76%, P=0.0177) or the co-infection group (31.65% vs 17.76%, P=0.0359) (Table 4). The FB findings showed that compared with the viral infection and atypical bacterial infection groups, the co-infection group presented more severe tracheal mucosal injury. The proportion of more severe mucosal erosion and/or necrosis was the highest in co-infection group (53.16% vs 35.51%, P=0.0174; 53.16% vs 39.34%, P=0.0176). Compared with the viral infection group, bronchial mucus plugs and plastic bronchitis were more frequently detected in children with atypical bacterial infections (18.18% vs 1.87%, P<0.001) and co-infections (10.13% vs 1.87%, P=0.0193). Compared with the atypical bacterial infection group, virus infection was more likely to give rise to alterations in bronchial lumen morphology, which included bronchial atresia (5.61% vs 1.19%, P=0.0043) and bronchiectasis (4.67% vs 0.42%, P=0.0007) (Table 4).

Clinical characteristics before and during the COVID-19 pandemic

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

Compared with before the COVID-19 pandemic, clinical symptoms and pulmonary signs in the enrolled children during the pandemic showed a shorter duration of cough [7 (5.10) days vs 6 (4.9) days; P<0.001], a decreased proportion of rhonchi dyspnea (38.11% vs 23.76%, P<0.001) and chest indrawing (3.46% vs 1.51%, P=0.0216), but an increased proportion of chest pain (1.89% vs 3.85%, P=0.0364), decreased breath sounds (47.87% vs 64.01%, P<0.001) and rales (49.92% vs 78.30%, P<0.001). CT scans revealed that the proportions of consolidation (91.76% vs 57.64%, P<0.001) and unilateral multilobar infiltrates (32.55% vs 22.05%, P<0.001) were higher than before the COVID-19 pandemic, but the proportions of bilateral multilobar infiltrates (28.57% vs 35.91%, P=0.0043) and pleural effusion (13.74% vs 21.42%, P=0.0002) were lower than before the COVID-19 pandemic. The FB findings revealed an increased proportion of mucosal hyperemia and/or edema (27.09% vs 89.01%, P<0.001), which corresponded to the decreased proportion of mucosal erosion and/or necrosis (72.91% vs 10.99%, P<0.001). Despite a significant increase in the proportion of bronchial mucus plugs (13.70% vs 18.82%, P=0.0126), there was a significant reduction in bronchial atresia (3.31% vs 0.27%, P<0.001) and bronchiectasis (1.57% vs 0.14%, P=0.0039). The above results suggest that lung inflammation in the enrolled children was significantly alleviated compared with before the COVID-19 pandemic (Table 5).

Table5 Comparison of clinical and laboratory findings before and during COVID-19 pandemic in children performed with FOB combined with BAL

Characteristic	Total n=1363	Before n=635	Ongoing n=728	P value
Clinical data				_
Duration of fever,mean(P25, P75) ^a	7(5,8)	7(5,9)	7(5,8)	0.4202
Duration of cough,mean(P25, P75) ^a	7(5,9)	7(5,10)	6(4,9)	<0.001
Fatigue ^b	17(1.25)	10(1.57)	7(0.96)	0.337
Dyspnea ^b	29(2.13)	19(2.99)	10(1.37)	0.0581
Wheezing ^b	78(5.72)	41(6.46)	37(5.08)	0.2941
Lack of appetite b	830(60.9)	379(59.69)	451(61.95)	0.4043
Abdominal pain ^b	227(16.65)	98(15.43)	129(17.72)	0.2747
Diarrhea ^b	100(7.34)	50(7.87)	50(6.87)	0.5323
Chest pain b	40(2.93)	12(1.89)	28(3.85)	0.0364
Physical sign				•
Decreased breath sounds ^b	770(56.49)	304(47.87)	466(64.01)	<0.001
Rales ^b	887(65.08)	317(49.92)	570(78.30)	<0.001
Rhonchi ^b	415(30.45)	242(38.11)	173(23.76)	<0.001

Tachypnea ^b	47(3.45)	19(2.99)	28(3.85)	0.4576
Chest indrawing b	33(2.42)	22(3.46)	11(1.51)	0.0216
T scan				
Consolidation b	1034(75.86)	366(57.64)	668(91.76)	<0.001
Single lobar infiltrate ^b	519(38.08)	245(38.58)	274(37.64)	0.7374
Multilobar infiltrates (unilateral) b	377(27.66)	140(22.05)	237(32.55)	<0.001
Multilobar infiltrates (bilateral) ^b	436(31.99)	228(35.91)	208(28.57)	0.0043
Pleural effusion ^b	236(17.31)	136(21.42)	100(13.74)	0.0002
Pericardial effusion ^b	37(2.71)	15(2.36)	22(3.02)	0.5065
iberoptic bronchoscopy				
Mucosal hyperemia and/or edema b	820(60.16)	172(27.09)	648(89.01)	<0.001
Mucosal erosion and/or necrosis b	543(39.84)	463(72.91)	80(10.99)	<0.001
Bronchial mucus plugs b	224(16.43)	87(13.70)	137(18.82)	0.0126
Plastic bronchitis ^b	171(12.55)	86(13.54)	85(11.68)	0.3255
Bronchial atresia ^b	23(1.69)	21(3.31)	2(0.27)	<0.001
Bronchiectasis ^b	11(0.81)	10(1.57)	1(0.14)	0.0039

Data are no. (%) of children, unless otherwise indicated. Percentages were calculated using the number of children with available data, rather than the number.

- a. Kruskal-Wallis H tests were conducted to compare groups.
- b. Fisher exact tests were conducted to compare groups.

Discussion

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

Respiratory pathogen detection in nasopharyngeal swabs, oropharyngeal swabs and even endotracheal aspirates may not fully represent the etiology of pneumonia[20]. Thus, most children with CAP may not receive treatment based on a reliable etiological diagnosis. Furthermore, the pathogen spectrum of respiratory tract infections is affected by age, geography, and environmental, social, economic and other factors. It is therefore necessary to definitively address the spectrum of respiratory pathogens involved in pediatric CAP. The aim of this study was to evaluate the etiologies in children with CAP requiring BAL. In addition, the influence of the COVID-19 pandemic on the pathogens and the clinical manifestations in the children were analyzed. We found that the positive rate of pathogen detection was 91.66%. The high etiological detection rate may be mainly attributable to our use of mRT-PCR on specimen from the foci of inflammation. The most common pathogen was M. pneumoniae, which was detected in more than four-fifths of all cases, with a remarkable over-representation among children older than 3 years of age. This proportion was higher than that reported in other studies (Lee et al. 45.3% in South Korea[4] and Gao et al. 37.5% in north China[3]. Considering that patients who required BAL in addition to intravenous medical treatment had more severe pneumonia, this difference may partly be explained by the differences in the studied populations. Virus was detected in 12.51% (186/1487) of our enrolled cases. Unlike our

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

results, one or more viruses were detected in 73% of children hospitalized for CAP in the United States[21]. Furthermore, a higher percentage of children (94.3%) were reported with severe acute respiratory infection in China during the 2009 H1N1 pandemic and post-pandemic period[22]. With the differences in study sites, populations, as well as study years and duration, the proportions varied largely between studies. Of the 186 children infected with virus, AdV was the most prevalent in the present study representing 34.41% (64/186) of cases, which was in line with a study in Cameroon among children with severe acute respiratory infections[23]. However, the majority of similar studies reported RSV as the most commonly detected viral pathogen[20,21]. In the present study, RSV ranked fifth with a relatively low positive detection rate of 10.22% (19/186). Co-infections were observed in nearly half of the patients (42.47%, 79/186) that tested positive for virus infection. This suggests that severe viral-related CAP is often accompanied by atypical bacterial infection. The COVID-19 pandemic and the NPIs undertaken during the pandemic significantly affected the transmission of common respiratory pathogens. Compared with before the COVID-19 pandemic, the overall detection rate of viral pathogens was lower during the COVID-19 pandemic. However, the detection rate of atypical bacterial pathogens increased. The decreased detection of AdV, HRV, Flu B, Flu A and HBoV greatly contributed to the overall reduction in viral pathogens. In accordance with our results, a significant decrease in the detection of AdV, Flu B and Flu A was also

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

observed in children with a lower respiratory tract infection during the COVID-19 pandemic in southern China[5] and a considerable reduction in all viral respiratory infections was observed in a large Italian tertiary hospital[6]. In a study conducted in southern China, the detection rates of M. pneumoniae using nasopharyngeal swabs of inpatients with acute respiratory infection were also unprecedentedly reduced from 20% in 2019 to 1.0% in 2020[7]. However, another study using BALF from a city in northern China, showed that M. pneumoniae was the most frequently detected pathogen, at a rate of up to 73.55%[24]. Furthermore, the detection of *M. pneumoniae* further increased despite the NPIs that were adopted during the COVID-19 pandemic. The main reason for this phenomenon might be the long-term colonization of M. pneumoniae in the upper respiratory tract[25]. In aspect to clinical manifestations, we found that children with atypical bacterial infections more frequently displayed a longer duration of fever, and a higher proportion of decreased breath sounds and rales. However, dyspnea, wheezing, diarrhea, rhonchi and chest indrawing were more frequent among children with a viral infection. Similar to other studies[26], compared with children with viral pneumonia, *M. pneumoniae*-positive children were significantly more likely to report a long duration of symptoms before hospitalization, and decreased breath sounds and rales, but were less likely to report dyspnea, wheezing, diarrhea, rhonchi and chest indrawing. Such findings may help inform clinicians of the preliminary differentiation between viral and atypical bacterial infections.

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

On CT scans, consolidation and unilateral lung infiltration were often seen in the atypical bacterial infection group, whereas bilateral lung infiltration was more common in the viral infection group, suggesting that pulmonary inflammation caused by M. pneumoniae is relatively limited to unilateral lung tissue, while viral infection affected bilateral lung tissues in nearly half of the children. This finding was consistent with another study that compared the radiographic findings of children hospitalized for CAP with and without M. pneumoniae using data from the EPIC study[27]. FB results indicated more serious inflammatory changes in the mucosa, increasing the likelihood of this condition developing into bronchial mucus plugs and even bronchial dendritic casts in *M. pneumoniae*-infected children. The presence of bronchial mucus plugs, as detected by FB, is independently associated with a longer time period to radiographic clearance in patients with refractory M. pneumoniae pneumonia[28]. Wang et al. reported that in 86.6% of children with plastic bronchitis the causative agent was M. pneumoniae[29] and this result was consistent with our findings. Bronchial atresia and/or bronchiectasis of the distal airway mostly occurred in children infected with virus. Despite few articles related to bronchial lumen morphological changes during the acute stage of pneumonia, our experienced bronchoscopists found that bronchial lumen dilation can be reversed with appropriate treatment. It was unfortunate that bronchial atresia was usually not reversible. Thus, the results highlighted

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

the necessity for careful management and long-term follow-up of patients with mucus plugs, plastic bronchitis and bronchial lumen morphological changes. Several studies have reported the impact of the COVID-19 pandemic on the pathogen spectrum of respiratory tract infections in children[5-7,24], but the corresponding differences in clinical manifestations have rarely been studied. During the COVID-19 pandemic, we found a decreased proportion of rhonchi, chest indrawing, bilateral lung infiltrates and bronchial lumen morphological changes, but a significantly higher proportion of decreased breath sounds, rales, consolidation, unilateral lung infiltrates and bronchial mucus plugs. Considering that the clinical manifestations of the children were consistent with a higher detection rate of M. pneumoniae, a possible explanation for this difference was a decrease in viral infection accompanied by an increase in M. pneumoniae infection. Therefore, wearing masks and social distancing in public places could effectively reduce the transmission of respiratory viruses, but did not reduce the infection rate of *M. pneumoniae*. Compared with before the COVID-19 pandemic, fewer children with bilateral multilobar infiltrates and pleural effusion were detected by CT scans, and mild inflammatory changes in the mucosa and decreased lumen morphological changes were detected by FB. Therefore, it is reasonable to deduce that the NPIs during the COVID-19 pandemic significantly alleviated lung inflammation compared with before the pandemic.

Several limitations should be taken into consideration in this present study.

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

First, our study was limited to children requiring BALF and did not include children receiving medical therapy alone or in need of intensive care, and therefore does not fully represent the distribution of characteristics of all CAP pathogens. Second, although testing for common respiratory viruses and atypical bacteria, bacterial detection was restricted to the panel of organisms covered by the SureX 13 respiratory pathogen multiplex kit. This may have resulted in underestimation of the overall detection rate for pathogens. Third, due to the implementation of NPIs, our sample collection time was interrupted and were not able to identify the season-dependent changes in the occurrence of CAP caused by each etiology. Despite these limitations, our study suggest that *M. pneumoniae* infection might be the greatest pediatric disease burden leading to CAP in northern China. Wearing masks and social distancing in public places can effectively reduce the transmission of respiratory viruses, but cannot reduce the infection rate of *M. pneumoniae*. In addition, the NPIs during the COVID-19 pandemic significantly reduced lung inflammation compared with before the pandemic. Our identifying changes in the pathogen spectrum and clinical characteristics might improve clinical management practices and emphasize the protective value of wearing masks and social distancing in children with Community-acquired pneumonia children. in

- 421 Acknowledgments The authors would like to thank the clinical staff,
- specifically the medical doctors and nurses, for their help with collecting clinical
- specimens, and all of the children and their parents for their participation and
- 424 cooperation.

References

- 1. Perin J, Mulick A, Yeung D, Villavicencio F, Lopez G, Strong KL, et al.
- Global, regional, and national causes of under-5 mortality in 2000-19: An
- 428 updated systematic analysis with implications for the Sustainable
- Development Goals. Lancet Child Adolesc Health. 2022;6:106-15.
- 2. Darby JB, Singh A, Quinonez R. Management of complicated pneumonia
- in childhood: A review of recent literature. Rev Recent Clin Trials.
- 432 2017;12:253-9.
- 3. Gao LW, Yin J, Hu YH, Liu XY, Feng XL, He JX, et al. The epidemiology of
- paediatric Mycoplasma pneumoniae pneumonia in North China: 2006 to
- 435 **2016**. Epidemiol Infect. 2019;147:e192.
- 436 4. Lee E, Kim CH, Lee YJ, Kim HB, Kim BS, Kim HY, et al. Annual and
- seasonal patterns in etiologies of pediatric community-acquired
- pneumonia due to respiratory viruses and Mycoplasma pneumoniae
- requiring hospitalization in South Korea. Bmc Infect Dis. 2020;20:132.
- 5. Liu P, Xu M, Cao L, Su L, Lu L, Dong N, et al. Impact of COVID-19
- pandemic on the prevalence of respiratory viruses in children with lower
- respiratory tract infections in China. Virol J. 2021;18:159.
- 6. Vittucci AC, Piccioni L, Coltella L, Ciarlitto C, Antilici L, Bozzola E, et al.
- The disappearance of respiratory viruses in children during the COVID-19
- pandemic. Int J Environ Res Public Health. 2021;18:9550.
- 7. Li L, Wang H, Liu A, Wang R, Zhi T, Zheng Y, et al. Comparison of 11

- respiratory pathogens among hospitalized children before and during the
- 448 COVID-19 epidemic in Shenzhen, China. Virol J. 2021;18:202.
- 8. Takashita E, Kawakami C, Momoki T, Saikusa M, Shimizu K, Ozawa H, et
- al. Increased risk of rhinovirus infection in children during the coronavirus
- disease-19 pandemic. Influenza Other Respir Viruses. 2021;15:488-94.
- 9. Agca H, Akalin H, Saglik I, Hacimustafaoglu M, Celebi S, Ener B. Changing
- epidemiology of influenza and other respiratory viruses in the first year of
- 454 COVID-19 pandemic. J Infect Public Health. 2021;14:1186-90.
- 10. Wan WY, Thoon KC, Loo LH, Chan KS, Oon L, Ramasamy A, et al. Trends
- in respiratory virus infections during the COVID-19 pandemic in singapore,
- 457 2020. JAMA Netw Open. 2021;4:e2115973.
- 11. Kuitunen I, Artama M, Mäkelä L, Backman K, Heiskanen-Kosma T, Renko
- M. Effect of social distancing due to the COVID-19 pandemic on the
- incidence of viral respiratory tract infections in children in finland during
- early 2020. Pediatr Infect Dis J. 2020;39:e423-7.
- 12. Collaborators GLRI. Estimates of the global, regional, and national
- 463 morbidity, mortality, and aetiologies of lower respiratory infections in 195
- countries, 1990-2016: A systematic analysis for the Global Burden of
- Disease Study 2016. Lancet Infect Dis. 2018;18:1191-210.
- 466 13. Yun KW, Wallihan R, Juergensen A, Mejias A, Ramilo O.
- Community-Acquired pneumonia in children: Myths and facts. Am J
- 468 Perinatol. 2019;36:S54-7.

- 14. Radhakrishnan D, Yamashita C, Gillio-Meina C, Fraser DD. Translational
- research in pediatrics III: Bronchoalveolar lavage. Pediatrics.
- 471 2014;134:135-54.
- 15. Wang L, Zhao M, Shi Z, Feng Z, Guo W, Yang S, et al. A GeXP-Based
- assay for simultaneous detection of multiple viruses in hospitalized
- 474 children with community acquired pneumonia. Plos One.
- 475 **2016**;11:e162411.
- 16. Midulla F, de Blic J, Barbato A, Bush A, Eber E, Kotecha S, et al. Flexible
- endoscopy of paediatric airways. Eur Respir J. 2003;22:698-708.
- 17. Experts Group of Pediatric Respiratory Endoscopy, Talent Exchange
- Serice Center of National Health Commission Endoscopy Committee,
- Pediatric Section of Chinese Medical Doctor Association, Pediatric
- Respiratory Endoscopy Committee, Endoscopists Section of Chinese
- Medical Doctor Association, Pediaric Interventional Respirology Group,
- 483 Maternal and Pediatric Minimally Inasive Section of Chinese Maternal and
- Child Health Association Bronchoscopy Collaboration Subgroup of
- Respirology Group, Pediatric Section of Chinese Medical Associatio.
- Guideline of pediatric flexible bronchoscopy in China (2018 version).
- Zhong Hua Shi Yong Er Ke Lin Chuang Za Zhi. 2018;13:983-989.
- 18. Chen D, Huang Y, Jiao A, Jin R, Liu X, Meng C, et al. Expert consensus on
- respiratory endoscopic interventional diagnosis and treatment of refractory
- pneumonia in Chinese children. Zhong Hua Shi Yong Er Ke Za Zhi.

- 491 **2019**;34:449-57.
- 19. Andronikou S, Goussard P, Sorantin E. Computed tomography in children
- with community-acquired pneumonia. Pediatr Radiol. 2017;47:1431-40.
- 494 20. Rhedin S, Lindstrand A, Hjelmgren A, Ryd-Rinder M, Ohrmalm L,
- Tolfvenstam T, et al. Respiratory viruses associated with
- community-acquired pneumonia in children: Matched case-control study.
- 497 Thorax. 2015;70:847-53.
- 498 21. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al.
- Community-acquired pneumonia requiring hospitalization among U.S.
- 500 Children. N Engl J Med. 2015;372:835-45.
- 22. Zhang C, Zhu N, Xie Z, Lu R, He B, Liu C, et al. Viral etiology and clinical
- 502 profiles of children with severe acute respiratory infections in China. Plos
- 503 One. 2013;8:e72606.
- 23. Kenmoe S, Tchendjou P, Vernet MA, Moyo-Tetang S, Mossus T,
- Njankouo-Ripa M, et al. Viral etiology of severe acute respiratory infections
- in hospitalized children in Cameroon, 2011-2013. Influenza Other Respir
- 507 Viruses. 2016;10:386-93.
- 508 24. Guo W, Cui X, Wang Q, Wei Y, Guo Y, Zhang T, et al. Clinical evaluation of
- metagenomic next-generation sequencing for detecting pathogens in
- 510 bronchoalveolar lavage fluid collected from children with
- community-acquired pneumonia. Front Med (Lausanne). 2022;9:952636.
- 512 25. Spuesens EB, Fraaij PL, Visser EG, Hoogenboezem T, Hop WC, van

Adrichem LN, et al. Carriage of Mycoplasma pneumoniae in the upper 513 respiratory tract of symptomatic and asymptomatic children: An 514 observational study. Plos Med. 2013;10:e1001444. 515 26. Li YT, Liang Y, Ling YS, Duan MQ, Pan L, Chen ZG. The spectrum of viral 516 517 pathogens in children with severe acute lower respiratory tract infection: A 3-year prospective study in the pediatric intensive care unit. J Med Virol. 518 2019;91:1633-42. 519 27. Kutty PK, Jain S, Taylor TH, Bramley AM, Diaz MH, Ampofo K, et al. 520 521 Mycoplasma pneumoniae Among Children Hospitalized with Community-acquired Pneumonia. Clin Infect Dis. 2019;68:5-12. 522 28. Huang L, Huang X, Jiang W, Zhang R, Yan Y, Huang L. Independent 523 524 predictors for longer radiographic resolution in patients with refractory Mycoplasma pneumoniae pneumonia: A prospective cohort study. Bmj 525 Open. 2018;8:e23719. 526 527 29. Wang L, Wang W, Sun JM, Ni SW, Ding JL, Zhu YL, et al. Efficacy of fiberoptic bronchoscopy and bronchoalveolar lavage in childhood-onset, 528

complicated plastic bronchitis. Pediatr Pulmonol. 2020;55:3088-95.